Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LU-TEMP pilot study of lutate plus temozolomide in SDH-associated pheochromocytoma/paraganglioma
ACTRN12621000802808Phase 2Recruiting
- Sponsor
- Royal North Shore Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of leuprolide and temozolomide in pheochromocytoma and Paraganglioma (PGL) (2 arms), sponsored by Royal North Shore Hospital. Primary endpoint: Objective response rate. Started Jun 2022; status: recruiting.
02
Drugs
leuprolidetemozolomide
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on ACTRN12621000802808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000802808.